Gowan Company Acquires Two Active Ingredients From Bayer

The acquisition includes active ingredients Fenamidone and Pencycuron as well as product registrations and trademarks including Consento, Reason, Monceren, and Prestige, and related intellectual property and labels.

Gowan Crop Protection Limited, an affiliate of Gowan Company, L.L.C., announced today that it has entered into agreements with Bayer AG to acquire rights to the active ingredients Fenamidone and Pencycuron.

The acquisition includes product registrations and trademarks including Consento, Reason, Monceren, and Prestige, and related intellectual property and labels for both fungicides. The transactions closed December 1, although Bayer and Gowan will work together over the next several months to facilitate an orderly hand-off and to maintain quality customer service in all geographies. The financial terms of the agreements were not disclosed.

Pencycuron is a foliar and seed treatment product for the control of diseases originating from Rhizoctania solani in various crops including cotton, rice, potatoes, turf and vegetables. It has broad presence in Japan, Brazil, India and Russia, among other countries.

Fenamidone is a product for control of diseases originating from water molds or the oomycetes class of fungi, key among them being downy mildew, late blight and early blight on grapes, vegetables, potatoes and ornamentals. With sales in the USA, Mexico, India, Russia, and Brazil, Fenamidone is a critical tool for many growers around the world.

A cornerstone of Gowan’s Muddy Boots philosophy is to help growers combat the challenges of pests and diseases. Gowan believes this acquisition will expand its core product offering and allow the company to better serve growers’ needs. Read more.

Scoop-logo (1346x354)
Read Next
ARA’s Hunter Carpenter breaks down the House-passed Farm Bill—and the critical pesticide labeling and permit reforms that got left behind. From the breakthrough on year-round E15 sales to the high-stakes battle over rail mergers, find out how these decisions impact your bottom line and license to operate.
Follow the Scoop
Get Daily News
Get Markets Alerts
Get News & Markets App